Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak

N/

Management of advanced melanoma in the COVID-19 era

N/

Yellow Plugs: An Additional Dermoscopic Criterion in the Diagnosis of Primary Cutaneous B-Cell Lymphoma

n/

Evidence for proton acceleration and escape from the Puppis A SNR using Fermi-LAT observations

Supernova remnants (SNRs) are the best candidates for galactic cosmic ray acceleration to relativistic energies via diffusive shock acceleration. The gamma-ray emission of SNRs can provide direct evidence of leptonic (inverse Compton and bremsstrahlung) and hadronic (proton-proton interaction and subsequently pion decay) processes. Puppis A is a ~ 4 kyr old SNR interacting with interstellar clouds which has been observed in a broad energy band, from radio to gamma-ray. We performed a morphological and spectral analysis of 14 years of observations with Fermi-LAT telescope in order to study its gamma-ray emission. We found a clear asymmetry in high-energy brightness between the eastern and western sides of the remnant, reminiscent to that observed in the X-ray emission. The eastern side, interacting with a molecular cloud, shows a spectrum which can be reproduced by a pion decay model. Moreover, we analyzed two gamma-ray sources located close to the remnant. The hardness of their spectra suggests that the gamma-ray emission can be due to particles escaping from the shock of Puppis A.Comment: Presented at the 38th International Cosmic Ray Conference (ICRC 2023), 8 pages, 2 figures, 3 table

An overview of treatment options for mild-to-moderate acne based on American Academy of Dermatology, European Academy of Dermatology and Venereology, and Italian Society of Dermatology and Venereology guidelines

Acne is a common inflammatory skin disorder affecting the pilosebaceous unit. Patients with mild-to-moderate acne can be treated with a combination of topical, systemic, and physical therapeutic approaches, with different results depending on patient, disease, and treatment characteristics. Herein we describe and discuss the common and alternative treatment options used for mild-to-moderate acne, by comparing three widely distributed guidelines (American Academy of Dermatology, European Academy of Dermatology and Venereology, and Italian Society of Dermatology and Venereology

Clinical and Dermoscopic Features of Melanocytic Lesions on the Face Versus the External Ear

Introduction Melanoma of the external ear is a rare condition accounting for 7-20% of all melanomas of the head and neck region. They present classical features of extra-facial melanomas clinically and dermoscopically. In contrast, facial melanomas show peculiar patterns in dermoscopy. Objectives To evaluate whether there are clinical and/or dermoscopic differences in melanocytic lesions located either at the external ear or on the face. Methods In this retrospective study we reviewed an image database for clinical and dermoscopic images of melanomas and nevi located either on the face or at the level of the external ear. Results 65 patients (37 men; 63.8%) with 65 lesions were included. We found no significant differences in comparing face melanomas with melanomas at the level of the external ear, neither clinically nor dermoscopically. However, we provided evidence for differences in some clinical and dermoscopic features of melanomas and nevi of the external ear. Conclusions In this study, we reported no significant differences in comparing melanomas on the face with melanomas of the external ear, both clinically and dermoscopically. Furthermore, we provided data on clinical and dermoscopic differences comparing nevi and melanoma of the external ear

Adalimumab-associated spondylodiscitis: a new or underestimated side effect?

N/

Pattern of response of unresectable and metastatic cutaneous squamous cell carcinoma to programmed death-1 inhibitors: A review of the literature

Cutaneous squamous cell carcinoma (cSCC) is the second most frequent nonmelanoma skin cancer (NMSC). The majority of in situ cSCC [cSCC (Tis)] can be cured surgically, while local advanced and metastatic ones require other treatments, but there are no therapies approved by U.S. Food and Drug Administration (FDA). Available treatments for these stages included radiotherapy, chemotherapy as cisplatin, but responses to these treatments are usually of short duration. Programmed death-1 (PD-1) inhibitors (pembrolizumab, nivolumab, and cemiplimab) are an innovative immunologic treatment that now has been shown to be useful for the treatment of advanced cSCC. Nowadays, data about the response rate with the use of PD-1 inhibitors in cSCC are still few and, especially, the duration of the response after the start of treatment is short. Moreover, the number of cases is too small to express the beneficial effects of these treatments, although most data reported in the literature show quite good response rates. This review focused on some of the studies and associated results through an interesting research on search engines of all the cases about these systemic drugs, analyzing effects and side effects, and the research has been conducted considering published cases since March 2016 to October 2019